Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Inclusion Criteria:

Metastatic hormone refractory prostate cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.
testosterone <50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.
Progressive disease after androgen deprivation.

Exclusion Criteria:

Patients whose clinical condition would make chemotherapy clearly indicated.
Patients who have received systemic chemotherapy for the treatment of metastatic disease.
Peripheral neuropathy > Grade 1
Prior anti-angiogenic therapy, including thalidomide.
Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.
Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
Patients with known brain metastases or history of brain metastases.
History of stroke within 6 months of treatment or other significant neurological limitations.
Patients who have received more than 2 prior investigational treatments.
Uncontrolled intercurrent illness
Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias